| P50 | author | Y. Lynn Wang | Q55164780 |
| | Ai-Lin Guo | Q80265766 |
| P2093 | author name string | J Ma | |
| | M Liu | |
| | P Lu | |
| | J J Buggy | |
| | S Cheng | |
| | R R Furman | |
| | M Coleman | |
| | J P Leonard | |
| P2860 | cites work | Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 |
| | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
| | Chronic lymphocytic leukemia | Q28236621 |
| | Aggressive lymphomas | Q28279743 |
| | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 |
| | Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles | Q33385676 |
| | Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia | Q33394487 |
| | In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells | Q33830733 |
| | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 |
| | Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy | Q34020276 |
| | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 |
| | The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 |
| | In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia | Q34078726 |
| | Early events in B cell activation | Q34101385 |
| | PI3K/p110{delta} is a novel therapeutic target in multiple myeloma | Q34124937 |
| | Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 |
| | The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia | Q34249777 |
| | The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 |
| | B cell antigen receptor signaling 101. | Q35818846 |
| | Mechanisms of B-cell lymphoma pathogenesis | Q36085626 |
| | Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia | Q36135185 |
| | CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells | Q36384860 |
| | SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma | Q36445884 |
| | B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. | Q37028635 |
| | Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? | Q37229081 |
| | B cell signaling and fate decision. | Q37614547 |
| | SYK inhibition and response prediction in diffuse large B-cell lymphoma | Q39453213 |
| | Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals | Q39586039 |
| | CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 |
| | The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 |
| | Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance | Q39798268 |
| | Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. | Q39965971 |
| | The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells | Q40069478 |
| | Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells | Q42446777 |
| | The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling | Q42475847 |
| | A proposal regarding reporting of in vitro testing results | Q42552338 |
| | Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells | Q42742097 |
| | Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia. | Q42933452 |
| | Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia | Q43119715 |
| | Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. | Q43196182 |
| | The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes | Q46542604 |
| | Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins | Q47290633 |
| | New strategies in the treatment of mantle cell lymphoma. | Q54504200 |
| | Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. | Q55050978 |
| | Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro | Q58436764 |
| P433 | issue | 3 | |
| P921 | main subject | ibrutinib | Q5984881 |
| P304 | page(s) | 649-657 | |
| P577 | publication date | 2013-11-25 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity | |
| P478 | volume | 28 | |